JP2003252755A - Healing-effect composition - Google Patents

Healing-effect composition

Info

Publication number
JP2003252755A
JP2003252755A JP2002057938A JP2002057938A JP2003252755A JP 2003252755 A JP2003252755 A JP 2003252755A JP 2002057938 A JP2002057938 A JP 2002057938A JP 2002057938 A JP2002057938 A JP 2002057938A JP 2003252755 A JP2003252755 A JP 2003252755A
Authority
JP
Japan
Prior art keywords
healing
gaba
composition
waves
appearances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002057938A
Other languages
Japanese (ja)
Inventor
Kenji Horie
健二 堀江
Hidehiko Yokogoshi
英彦 横越
Shinji Azumaguchi
伸二 東口
Busaku Kin
武祚 金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PHARMAFOODS KENKYUSHO KK
Pharma Foods Research Co Ltd
Original Assignee
PHARMAFOODS KENKYUSHO KK
Pharma Foods Research Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PHARMAFOODS KENKYUSHO KK, Pharma Foods Research Co Ltd filed Critical PHARMAFOODS KENKYUSHO KK
Priority to JP2002057938A priority Critical patent/JP2003252755A/en
Publication of JP2003252755A publication Critical patent/JP2003252755A/en
Pending legal-status Critical Current

Links

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide a healing-effect composition directly having influence on electroencephalogram in an ordinarily edible food form and capable of bringing about healing state and a food containing the composition. <P>SOLUTION: The present invention relates to the GABA-containing healing- effect composition directly increasing appearance of brain alpha wave and decreasing appearance of beta wave and positively imparting healing feeling in which a ratio of appearance frequency of the beta wave to appearance frequency of alpha wave exhibits a value smaller than 1 by orally ingesting GABA and the food containing the composition. <P>COPYRIGHT: (C)2003,JPO

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【発明の属する技術分野】本発明はGABAを含有する
癒し効果組成物に関する。更に上記癒し効果組成物を含
有する飲食品に関する。
TECHNICAL FIELD The present invention relates to a healing effect composition containing GABA. Further, it relates to a food or drink containing the above-mentioned healing effect composition.

【0002】[0002]

【従来の技術】ストレスの多い現代社会において「癒
し」とは非常に重要な要因である。
2. Description of the Related Art "Healing" is a very important factor in a stressful modern society.

【0003】現代において「癒し」効果をもたらす因子
は数多く存在する。例えば、音楽、ペット、おいしい食
事、温泉、旅行などが挙げられる。しかし上記述のもの
は、ヒトそれぞれの好みが大きな要因となる為、一概に
全ての人に対し「癒し」効果を発揮するとは限らない。
In modern times, there are many factors that provide a "healing" effect. For example, music, pets, delicious meals, hot springs, and travel. However, the above-mentioned ones do not always exert a "healing" effect on all people, because the taste of each person is a major factor.

【0004】一般的にヒトの情緒を表す指標として、脳
波による表現方法がある。
[0004] Generally, as an index showing human emotions, there is a method of expression by electroencephalogram.

【0005】人の脳波には、その周波数によって3.5
Hz以下のデルタ波、3.5Hz〜7.5Hzのシータ
波、7.5Hz〜13.5Hzのアルファ波および1
3.5Hzを超えるベータ波が存在する。これら脳波の
うちで、アルファ波はリラックスしている時に増加し、
ストレスが負荷されると減少することが知られている。
反面ベータ波は、脳内が覚醒し興奮している状態で出現
する脳波であることが知られている。
A human brain wave has a frequency of 3.5 depending on its frequency.
Hz delta wave, 3.5 Hz to 7.5 Hz theta wave, 7.5 Hz to 13.5 Hz alpha wave and 1
There are beta waves above 3.5 Hz. Of these electroencephalograms, alpha waves increase during relaxation,
It is known to decrease when stress is applied.
On the other hand, beta waves are known to appear when the brain is awake and excited.

【0006】アルファ波の出現状態はリラックス度の指
標としてしばしば用いられており、近年のストレス社会
において、アルファ波を積極的に増強させてリラックス
させようとする試みが様々行われている。しかし興奮し
ている時のベータ波の調節及び減少については言及され
ていない。
The appearance state of alpha waves is often used as an index of the degree of relaxation, and in recent stressful society, various attempts have been made to positively enhance alpha waves to relax them. However, no mention is made of the regulation and reduction of beta waves when excited.

【0007】GABA(ギャバ、γ−アミノ酪酸)は生
体内特に脳内に広く分布されている事が知られており、
抑制系の神経伝達物質として知られている。しかし、G
ABAは血液脳関門を通過しないと言われており、従っ
て経口で摂取したGABAによって、脳中枢神経系にお
けるGABA遊離量は通常影響しない。
It is known that GABA (gaba, γ-aminobutyric acid) is widely distributed in the living body, especially in the brain,
It is known as a suppressor neurotransmitter. But G
ABA is said not to cross the blood-brain barrier, so GABA taken orally does not normally affect GABA release in the central nervous system of the brain.

【0008】[0008]

【発明が解決しようとする課題】本発明の目的は、通常
食することが可能な食品形態で、脳波に直接影響する組
成物を提供する事にある。
SUMMARY OF THE INVENTION An object of the present invention is to provide a composition which directly affects the electroencephalogram in a food form which can be eaten normally.

【0009】日常的に必要に応じて摂取することが可能
であり、アルファ波を効果的に増強し同時にベータ波を
積極的に減少させることにより「癒し状態」をもたらす
ことのできる癒し組成物および本発明組成物を含有する
食品を提供することである。
A healing composition which can be taken on an as-needed basis on a daily basis, and which can bring about a "healing state" by effectively enhancing alpha waves and at the same time actively decreasing beta waves, and It is to provide a food containing the composition of the present invention.

【0010】[0010]

【課題を解決するための手段】本発明者等は鋭意検討し
た結果、GABAを経口的に摂取する事により、脳アル
ファ波の出現を増加させ、更にはベータ波の出現を減少
させる効果があることを見出した。GABAは抑制系の
神経伝達物質であるが、上記述の様に一般的には血液脳
関門を通過しない事が報告されており、経口摂取により
脳波に直接影響することは予想外の事である。そしてこ
の知見に基づいて、本発明を完成するに至った。
Means for Solving the Problems As a result of intensive studies by the present inventors, oral ingestion of GABA has the effect of increasing the appearance of cerebral alpha waves and further decreasing the appearance of beta waves. I found that. Although GABA is a neurotransmitter of the suppressive system, it has been reported that it generally does not cross the blood-brain barrier as described above, and it is unexpected that oral intake directly affects EEG. . The present invention has been completed based on this finding.

【0011】即ち、本発明の癒し効果組成物は、GAB
Aを有効成分として含有することを特徴とする。
That is, the healing composition of the present invention is GAB.
It is characterized by containing A as an active ingredient.

【0012】また、本発明の癒し効果組成物は、脳波で
あるアルファ波の出現回数を上昇させ、同時にベータ波
の出現回数を減少させ、そのベータ波の出現回数/アル
ファ波の出現回数の比が1より小さい値を示すという癒
し効果を表すことを特徴とする。
Further, the healing composition of the present invention increases the number of appearances of alpha waves, which are brain waves, and at the same time reduces the number of appearances of beta waves, and the ratio of the number of appearances of beta waves / the number of appearances of alpha waves. Is characterized by exhibiting a healing effect of showing a value smaller than 1.

【0013】そして本発明の癒し効果組成物は、GAB
Aを5〜70質量%含有することが好ましい。
The healing composition of the present invention is GAB.
It is preferable to contain A in an amount of 5 to 70 mass%.

【0014】また、本発明の飲食品は、上記癒し効果組
成物を含有することを特徴とする。
The food or drink of the present invention is characterized by containing the above-mentioned healing effect composition.

【0015】本発明によれば、経口摂取することで直接
脳アルファ波出現を増加させ、ベータ波の出現を減少さ
せることによって生じる「癒し感」を積極的に与える、
安全性の高い癒し効果組成物及びそれを含有する飲食品
を提供することができる。
According to the present invention, oral ingestion directly increases the cerebral alpha wave appearance and positively gives a "healing sensation" produced by decreasing the beta wave appearance.
It is possible to provide a highly safe healing effect composition and foods and drinks containing the same.

【0016】[0016]

【発明の実施の形態】以下、この発明の好適な実施形態
について説明する。
BEST MODE FOR CARRYING OUT THE INVENTION Preferred embodiments of the present invention will be described below.

【0017】本発明の癒し効果組成物の有効成分である
GABAは、食品の成分として茶、野菜類、穀類等に微
量含まれているアミノ酸の一種、γ―アミノ酪酸を指
す。
GABA, which is an active ingredient of the healing composition of the present invention, refers to γ-aminobutyric acid, which is one of the amino acids contained in trace amounts in tea, vegetables, cereals and the like as a food ingredient.

【0018】本発明においては、GABAの製造法とし
て大量且つ安価にGABAを得ることができる乳酸菌に
よる発酵法が好ましい。例えば、グルタミン酸ソ−ダ、
ブドウ糖、パン酵母エキス、酢酸ナトリウム、硫酸マグ
ネシウム等を含む培養液に、乳酸菌(ラクトバチルス
ブレビス(IFO12005株)、ラクトバチルスヒル
ガルディーK−3株(FERM P−18422)等)
の培養液を添加し、20〜30℃で、1〜3日間培養
し、この培養液を、加熱殺菌後、濾過して濾液を得る。
なお、乳酸菌としてラクトバチルス ヒルガルディーK
−3株(FERM P−18422)を用いた場合、培
養液中のGABA含量は約5質量%、固形分当りに換算
するとGABAは約70%を占める。
In the present invention, a preferred method for producing GABA is a fermentation method using a lactic acid bacterium capable of obtaining GABA in large quantities and at low cost. For example, sodium glutamate,
Add lactic acid bacteria (Lactobacillus) to a culture solution containing glucose, baker's yeast extract, sodium acetate, magnesium sulfate, etc.
Brevis (IFO12005 strain), Lactobacillus hirugardi K-3 strain (FERM P-18422), etc.)
The culture solution is added, and the mixture is cultured at 20 to 30 ° C. for 1 to 3 days. The culture solution is sterilized by heating and then filtered to obtain a filtrate.
As lactic acid bacteria, Lactobacillus hirugardi K
When strain -3 (FERM P-18422) is used, the GABA content in the culture broth is about 5% by mass, and GABA accounts for about 70% in terms of solid content.

【0019】この濾液は、適宜濃縮してそのまま、又は
更に乾燥して粉末として、本発明の癒し効果組成物とし
て用いることができる。また、上記濾液をカラムクロマ
トグラフィー等の処理に供することにより、GABAを
更に精製することもできる。例えば、イオン交換樹脂D
SR−01(商品名、三菱化学株式会社製)を用いたカ
ラムクロマトグラフィーを行なうことにより、よりGA
BA含量の高い(80%質量%以上)組成物を得ること
ができる。
This filtrate can be used as the healing effect composition of the present invention by appropriately concentrating it as it is or further drying it as a powder. GABA can be further purified by subjecting the filtrate to a treatment such as column chromatography. For example, ion exchange resin D
By performing column chromatography using SR-01 (trade name, manufactured by Mitsubishi Chemical Corporation), more GA
A composition having a high BA content (80% by mass or more) can be obtained.

【0020】本発明の癒し効果組成物におけるGABA
の含有量は、特に制限はないが、5〜70質量%が好ま
しく、20〜70質量%がより好ましい。
GABA in the healing composition of the present invention
The content of is not particularly limited, but is preferably 5 to 70 mass%, more preferably 20 to 70 mass%.

【0021】癒し効果組成物におけるGABAの含有量
が5質量%未満であると飲食品に添加するときに、癒し
効果が期待できる量を添加するのが困難になり、また、
70質量%超であると逆に精製にコストがかかるため好
ましくない。
When the content of GABA in the healing effect composition is less than 5% by mass, it becomes difficult to add a sufficient healing effect when added to foods and drinks.
On the other hand, if it exceeds 70% by mass, purification is costly, which is not preferable.

【0022】本発明の癒し効果組成物の形態は、特に制
限はなく、例えば、顆粒、粉末、錠剤、液体等が挙げら
れる。
The form of the healing composition of the present invention is not particularly limited, and examples thereof include granules, powders, tablets and liquids.

【0023】本発明の癒し効果組成物の有効摂取量は、
具体的な症状、年齢等により変わるが、通常、GABA
換算で、一人当たり10〜3000mg/日が好まし
く、100〜500mg/日がより好ましい。
The effective intake of the healing composition of the present invention is
GABA usually varies depending on specific symptoms, age, etc.
In terms of conversion, 10 to 3000 mg / day is preferable, and 100 to 500 mg / day is more preferable.

【0024】本発明における「癒し」とは、アルファ波
の出現回数を増加させ、同時にベータ波の出現回数を減
少させることをいう。その際、(ベータ波の出現回数)
/(アルファ波の出現回数)の比が1より少ない時の状
態を「癒し」といい、本比の値が小さくなる程、癒し効
果が大きいと判断される。
The "healing" in the present invention means increasing the number of appearances of alpha waves and simultaneously decreasing the number of appearances of beta waves. At that time, (the number of times the beta wave appears)
The state where the ratio of / (number of appearances of alpha waves) is less than 1 is called “healing”, and the smaller the value of this ratio, the greater the healing effect.

【0025】本発明の癒し効果組成物を飲食品に添加す
る場合、その添加量は、適宜設定できるが、通常、GA
BA換算で0.05〜20質量%が好ましく、0.1〜
10質量%がより好ましい。癒し効果組成物の添加量が
上記範囲外であると、充分な癒し効果を付与できない
か、あるいは飲食品の風味に影響がでる。
When the healing effect composition of the present invention is added to foods and drinks, the addition amount can be appropriately set, but it is usually GA.
0.05-20 mass% in terms of BA is preferable, and 0.1
10 mass% is more preferable. If the amount of the healing effect composition added is out of the above range, a sufficient healing effect cannot be imparted or the flavor of the food or drink is affected.

【0026】上記飲食品としては、特に制限はないが、
例えば、パン、ケーキ、菓子(クッキー、スナック菓
子、ガム、チョコレート等)、飲料(清涼飲料、ミネラ
ルウォーター、嗜好飲料、アルコール飲料等)、サプリ
メント(錠剤、ソフトカプセル等)が挙げられる。
The food and drink are not particularly limited,
Examples thereof include bread, cakes, confectionery (cookies, snacks, gums, chocolates, etc.), beverages (soft drinks, mineral water, favorite beverages, alcoholic beverages, etc.), and supplements (tablets, soft capsules, etc.).

【0027】[0027]

【実施例】以下、実施例を挙げて本発明を具体的に説明
するが、本発明はこれらに限定されるものではない。
The present invention will be specifically described below with reference to examples, but the present invention is not limited thereto.

【0028】実施例1 乳酸菌発酵GABAの調製 表1に示す割合で各成分を含有する発酵原料(pH5.
0)50Lを、90℃で10分間加熱殺菌した後、キム
チ由来の乳酸菌(ラクトバチルスヒルガルディーK−3
株(FERM P−18422))培養液50mLを接
種し、30℃で3日間培養した。なお、発酵終了後の発
酵液のGABA含量は51g/Lであった。この発酵液
を90℃で10分間加熱殺菌した後、濾過助剤を加えて
ろ過し、得られたろ液を真空濃縮機で濃縮した後、凍結
乾燥機にて乾燥し、粉砕して粉末化して乳酸菌発酵GA
BA組成物(GABA含量:65質量%)を得た。
Example 1 Preparation of Lactobacillus fermented GABA Fermentation raw materials (pH 5.
0) After sterilizing 50 L by heating at 90 ° C. for 10 minutes, kimchi-derived lactic acid bacteria (Lactobacillus hirugardi K-3
Strain (FERM P-18422)) culture solution (50 mL) was inoculated and cultured at 30 ° C. for 3 days. The GABA content of the fermented liquid after the fermentation was 51 g / L. This fermentation broth was sterilized by heating at 90 ° C. for 10 minutes, then a filter aid was added and filtered, and the obtained filtrate was concentrated with a vacuum concentrator, dried with a freeze dryer, pulverized into powder. Lactic acid bacteria fermentation GA
A BA composition (GABA content: 65% by mass) was obtained.

【0029】[0029]

【表1】 [Table 1]

【0030】尚、GABA醗酵原料としてはグルタミン
酸ソーダの他にグルタミン酸及び小麦グルテン、焼酎粕
タンパク等をグルタミン酸源としても差し支えない。
As the GABA fermentation raw material, glutamic acid, wheat gluten, shochu lees protein, etc. may be used as a glutamic acid source in addition to sodium glutamate.

【0031】試験例1 GABA濃度の測定 GABA濃度は、以下の方法により測定した。Test Example 1 GABA concentration measurement The GABA concentration was measured by the following method.

【0032】各試料を0.2Nクエン酸ナトリウム緩衝
液(pH2.2)で適宜希釈後、遠心分離又はろ過して
固形物を除去し、測定試料とした。GABAとグルタミ
ン酸の含量はアミノ酸含量測定の常法に従って高速液体
クロマトグラフで以下の条件で分析した。 使用機器:(株)島津製作所製の高速液体クロマトグラ
フLC−9A 分析用カラム:強酸性陽イオン交換樹脂カラムShin
−pack Isc−07Na型 移動層緩衝液:(株)島津製作所製のアミノ酸移動層キ
ットNa型 移動層流量:0.3ml/分 反応層1:0.04%次亜塩素酸ナトリウム溶液(pH
10のホウ酸−炭酸緩衝液500mlに対して次亜塩素
酸0.2ml) 反応層2:(株)島津製作所製のアミノ酸分析キットO
PA試薬 反応層流量:0.2ml/分 検出:蛍光検出 Ex348nm、Em450nm
Each sample was appropriately diluted with a 0.2N sodium citrate buffer (pH 2.2), and then centrifuged or filtered to remove solids, and used as a measurement sample. The contents of GABA and glutamic acid were analyzed by a high performance liquid chromatograph under the following conditions according to the usual method for measuring the amino acid content. Equipment used: High-performance liquid chromatograph LC-9A manufactured by Shimadzu Corporation Analytical column: Strongly acidic cation exchange resin column Shin
-Pack Isc-07 Na type moving layer buffer: amino acid moving layer kit manufactured by Shimadzu Corporation Na type moving layer flow rate: 0.3 ml / min Reaction layer 1: 0.04% sodium hypochlorite solution (pH
10 ml of boric acid-carbonate buffer solution (500 ml) and hypochlorous acid (0.2 ml) Reaction layer 2: Amino acid analysis kit O manufactured by Shimadzu Corporation
Flow rate of PA reagent reaction layer: 0.2 ml / min Detection: Fluorescence detection Ex348 nm, Em450 nm

【0033】実施例2 GABA摂取によるアルファ波及びベータ波出現回数 実施例1で得られた本発明組成物摂取によるアルファ波
の出現効果を調べた。まず、被験者は外部から遮断され
た室内(25℃、40ルクス)にて脳波を1時間測定し
た。脳波測定には脳波計多用途テレメーター(NEC)
を用いた。
Example 2 Number of appearance of alpha wave and beta wave by ingestion of GABA The effect of alpha wave appearance by ingestion of the composition of the present invention obtained in Example 1 was examined. First, the test subject measured an electroencephalogram for 1 hour in a room (25 ° C, 40 lux) shielded from the outside. EEG multi-purpose telemeter (NEC)
Was used.

【0034】測定は被験者10名に対して行い、官能試
験実施前20分間のアルファ波を脳波形より読み取り、
その値を各人の通常状態(100%)とした。官能試験
直後から20分毎5分間のアルファ波、ベータ波の出現
回数を算出し、合計回数グラフ化した。
The measurement was carried out on 10 subjects, and the alpha wave for 20 minutes before the sensory test was carried out was read from the brain waveform,
The value was set as the normal state (100%) of each person. Immediately after the sensory test, the number of appearances of alpha waves and beta waves was calculated every 20 minutes for 5 minutes, and the total number of times was graphed.

【0035】アルファ波の出現回数を図1に、(ベータ
波の出現回数)/(アルファ波の出現回数)の比を図2
に示す。
FIG. 1 shows the number of appearances of alpha waves, and FIG. 2 shows the ratio of (number of appearances of beta waves) / (number of appearances of alpha waves).
Shown in.

【0036】本結果より、GABA摂取によりアルファ
波の出現回数が増加する現象が認められた。更にベータ
波の現象も認められ、(ベータ波の出現回数)/(アル
ファ波の出現回数)との比を取ったところ1以下になる
事が示され、癒し効果が非常に大きいことが示唆され
る。
From these results, it was confirmed that the number of appearances of alpha waves was increased by GABA ingestion. Furthermore, the phenomenon of beta waves was also recognized, and it was shown that the ratio of (the number of appearances of beta waves) / (the number of appearances of alpha waves) was 1 or less, suggesting that the healing effect is very large. It

【0037】実施例3 以下特に限定するものではないが、本発明の癒し効果組
成物を含有する食品を挙げる。
Example 3 Hereinafter, although not particularly limited, foods containing the healing effect composition of the present invention will be mentioned.

【0038】打錠状食品の処方例 還元麦芽糖 71mg 結晶セルロ−ス 70mg ショ糖エステル 9mg 本発明組成物 170mg(GABAとして10
0mg)
Formulation Example of Tableted Food Reduced maltose 71 mg Crystalline cellulose 70 mg Sucrose ester 9 mg The composition of the present invention 170 mg (10 as GABA
0 mg)

【0039】[0039]

【発明の効果】以上説明した様に本発明によれば、GA
BA組成物により、アルファ波の出現回数を増加させ、
更にはベータ波の出現回数を減少させる効果を初めて発
見した。
As described above, according to the present invention, the GA
The BA composition increases the number of appearances of alpha waves,
Furthermore, we have discovered for the first time the effect of reducing the number of beta waves.

【0040】本発見により、ストレスからなる苛立ちを
直接静め、癒し効果のある組成物並びにその組成物を含
有してなる食品を提供でき、本発明の社会的貢献度は大
きい。
By the present discovery, it is possible to provide a composition having a healing effect by directly calming stress irritation and a food containing the composition, and the social contribution of the present invention is great.

【図面の簡単な説明】[Brief description of drawings]

【図1】実施例2におけるアルファ波の出現回数を示し
た図である。
FIG. 1 is a diagram showing the number of appearances of alpha waves in a second embodiment.

【図2】実施例2における(ベータ波の出現回数)/
(アルファ波の出現回数)の比を示した図である。
[FIG. 2] (Number of appearances of beta wave) in Example 2 /
It is the figure which showed the ratio of (the appearance frequency of an alpha wave).

───────────────────────────────────────────────────── フロントページの続き (72)発明者 金 武祚 京都府京都市南区吉祥院石原堂の後西町24 番5号 株式会社ファーマフーズ研究所内 Fターム(参考) 4B018 MD19 MD86 ME14 4C206 AA01 AA02 FA45 MA01 MA04 MA10 MA72 NA14 ZA05 ZC41   ─────────────────────────────────────────────────── ─── Continued front page    (72) Inventor Kim Takehisa             24 Koshinishi-cho, Kichijoin Ishihara-do, Minami-ku, Kyoto-shi, Kyoto Prefecture             No. 5 within Pharma Foods Laboratories, Inc. F-term (reference) 4B018 MD19 MD86 ME14                 4C206 AA01 AA02 FA45 MA01 MA04                       MA10 MA72 NA14 ZA05 ZC41

Claims (4)

【特許請求の範囲】[Claims] 【請求項1】 GABAを有効成分として含有すること
を特徴とする、癒し効果組成物。
1. A healing effect composition comprising GABA as an active ingredient.
【請求項2】 癒し効果が、脳波であるアルファ波の出
現回数を上昇させ、同時にベータ波の出現回数を減少さ
せ、そのベータ波の出現回数/アルファ波の出現回数の
比が1より小さい値を示す効果を表すことを特徴とする
請求項1記載の癒し効果組成物。
2. The healing effect increases the number of appearances of alpha waves, which are brain waves, and simultaneously decreases the number of appearances of beta waves, and the ratio of the number of appearances of beta waves / the number of appearances of alpha waves is smaller than 1. The healing effect composition according to claim 1, which exhibits the effect of
【請求項3】 GABAを5〜70質量%含有すること
を特徴とする請求項1または2記載の癒し効果組成物。
3. The healing effect composition according to claim 1 or 2, which contains GABA in an amount of 5 to 70% by mass.
【請求項4】 請求項1から3いずれか記載の癒し効果
組成物を含有することを特徴とする飲食品。
4. A food or drink comprising the composition for healing effect according to any one of claims 1 to 3.
JP2002057938A 2002-03-04 2002-03-04 Healing-effect composition Pending JP2003252755A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2002057938A JP2003252755A (en) 2002-03-04 2002-03-04 Healing-effect composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002057938A JP2003252755A (en) 2002-03-04 2002-03-04 Healing-effect composition

Publications (1)

Publication Number Publication Date
JP2003252755A true JP2003252755A (en) 2003-09-10

Family

ID=28668076

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002057938A Pending JP2003252755A (en) 2002-03-04 2002-03-04 Healing-effect composition

Country Status (1)

Country Link
JP (1) JP2003252755A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005232045A (en) * 2004-02-18 2005-09-02 Taiyo Kagaku Co Ltd Anti-stressing and relaxing composition
JP2006061088A (en) * 2004-08-27 2006-03-09 Pharma Foods International Co Ltd Concentration power-improving drink or food
WO2006041158A1 (en) * 2004-10-14 2006-04-20 Daikin Industries, Ltd. Method for modifying the ambience, and spray liquid and sprayer used in the method
JP2007031309A (en) * 2005-07-25 2007-02-08 Tokiwa Yakuhin Kogyo Kk Anti-stress composition
JP2011116666A (en) * 2009-11-30 2011-06-16 Api Co Ltd Anti-stress agent containing lactic bacterium-fermented royal jelly and method for producing the same
JP2014047213A (en) * 2012-08-29 2014-03-17 Marine Bioprocess Co Ltd Composition for releasing stress or for improving sleep disorder which contains fermented substance of mixture of oyster and seaweeds as active ingredient, and method of manufacturing the same

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005232045A (en) * 2004-02-18 2005-09-02 Taiyo Kagaku Co Ltd Anti-stressing and relaxing composition
JP2006061088A (en) * 2004-08-27 2006-03-09 Pharma Foods International Co Ltd Concentration power-improving drink or food
WO2006041158A1 (en) * 2004-10-14 2006-04-20 Daikin Industries, Ltd. Method for modifying the ambience, and spray liquid and sprayer used in the method
JP2007031309A (en) * 2005-07-25 2007-02-08 Tokiwa Yakuhin Kogyo Kk Anti-stress composition
JP2011116666A (en) * 2009-11-30 2011-06-16 Api Co Ltd Anti-stress agent containing lactic bacterium-fermented royal jelly and method for producing the same
JP2014047213A (en) * 2012-08-29 2014-03-17 Marine Bioprocess Co Ltd Composition for releasing stress or for improving sleep disorder which contains fermented substance of mixture of oyster and seaweeds as active ingredient, and method of manufacturing the same

Similar Documents

Publication Publication Date Title
KR100908254B1 (en) Antiallergic composition
KR102127911B1 (en) The composition of fermented beverage for immunity enhancement and method for production thereof
JP7432745B2 (en) A novel Lactobacillus sakei HEM224 strain, and a composition for treating inflammation or asthma containing the above strain or a culture thereof
JP5592640B2 (en) Antistress agent containing lactic acid bacteria fermented royal jelly, method for producing the same, hypothalamus-pituitary-adrenocortical activity inhibitor, and sympathetic-adrenal medullary activity inhibitor
JP4596304B2 (en) Growth hormone secretion promoting composition
JP2008245569A (en) Lactobacillus composition having high antiallergic activity and method for producing this lactobacillus
JP6991092B2 (en) Sleep quality improver
EP3932485A1 (en) Composition containing plant-derived extract and/or plant-derived processed product
JP6139217B2 (en) Method for producing D-amino acid
KR20160013069A (en) Compositions comprising a mixture of bacteria comprising pediococcus and lactobacillus and methods for decreasing the effects of alcohols
JP2003252755A (en) Healing-effect composition
JP4817087B2 (en) Bioactive extract
WO2002100393A1 (en) Compositions for ameliorating attention-deficient/hyperactivity disorder
JP5804391B2 (en) Anti-glycation agent
WO2007108071A1 (en) Antistress composition and food and drink containing the same
JP7404234B2 (en) Equol production promoter and food or drink composition for promoting equol production containing the same
JP2005255670A (en) Hypotensive peptide derived from royal jelly
JP2003088335A (en) Food composition for improving urination function, and good and drink containing the same
JP2003327528A (en) Immunocompetence-improving composition
JP2011093815A (en) Antiallergic agent or anti-atopic inflammatory agent containing lees of sweet potato distilled spirit or substance derived therefrom
JP2007063236A (en) Composition for improving quality of sleep
JP2006001922A (en) Allergy inhibitory composition
TWI842719B (en) Uses of Yeast Mannan
JP7008108B2 (en) Applications for treating or ameliorating sleep disorders using Lactobacillus brevis ProGA28 and its metabolites
JP7300121B2 (en) Anti-glycation composition and method for producing anti-glycation composition

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081028

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090310